Related by context. All words. (Click for frequent words.) 65 JAK2 inhibitor 63 including eniluracil ADH 63 non nucleoside HCV 63 oral prodrug 63 THR beta agonist 63 PRT# 63 PNP inhibitor 63 HCV polymerase inhibitor 62 PDE4 inhibitor 62 preclinically 62 targeting CD# 62 AEG# 62 receptor tyrosine kinase inhibitor 62 systemically administered 62 CEQ# 62 MT# MEDI 62 IMA# 62 forodesine 62 AAG geldanamycin analog 61 GRN# 61 alvespimycin 61 Phase IIb trials 61 CYT# potent vascular disrupting 61 Nanobody 61 XmAb ® 61 targeted radiotherapeutic 61 lintuzumab SGN 61 Lisofylline LSF 61 elotuzumab 61 SinuNase ™ 61 rxRNA 61 SAR# [004] 61 cMET 61 orally bioavailable 60 liposomal formulation 60 acetonide FA 60 Archexin 60 Panzem NCD 60 Prodarsan ® 60 polymerase inhibitor 60 rALLy clinical trial 60 TBC# 60 Sudhir Agrawal D.Phil 60 antisense drug 60 MAGE A3 ASCI 60 compound perifosine 60 Tarvacin TM 60 Marqibo TM 60 Zybrestat 60 HGS ETR1 60 TKM ApoB 60 investigational HCV polymerase 60 mGluR5 negative 60 mertansine 60 molecular imaging radiopharmaceutical 60 IAP inhibitor 60 antibody MAb 60 JAK1 60 R#/MEM # 60 GSK# [002] 60 investigational humanized monoclonal antibody 60 Omacetaxine 59 ganetespib 59 dasatinib Sprycel ® 59 JAK inhibitors 59 TACI Ig 59 Solazed TM 59 TELINTRA 59 phase IIa clinical 59 PANVAC VF 59 deforolimus 59 Personalized Immunotherapy 59 Solazed 59 OMP #R# 59 Phase 2a clinical trials 59 orally administered inhibitor 59 Factor VIIa 59 XL# XL# 59 HCV protease inhibitor 59 refractory gout 59 Panzem R 59 ATL# [002] 59 FOLOTYN ® 59 MEK inhibitor 59 metaglidasen 59 isoform selective 59 HCV protease inhibitors 59 MGd 59 therapeutic monoclonal antibody 59 IAP inhibitors 59 antisense inhibitors 59 phase IIb clinical 59 Phase IIb clinical trials 59 CRLX# 59 virus HCV protease inhibitor 59 XL# XL# XL# 59 HCV protease 59 CCR9 antagonist 59 IND submission 59 DPX Survivac 59 pan HDAC inhibitor 59 Phase #b/#a clinical 59 JAK inhibitor 59 leading oral taxane 59 ALN PCS 59 VitiGam 59 SAR# [002] 59 midstage trials 58 pomalidomide 58 PLK1 SNALP 58 Chimigen TM 58 polysaccharide polymer 58 investigational pan BCR 58 huC# DM4 58 Exherin TM 58 Trofex 58 TASKi2 58 potently inhibit 58 Prodarsan R 58 multi kinase inhibitor 58 TRO# 58 systemic RNAi therapeutic 58 novel peptide 58 CR# vcMMAE 58 Sym# 58 MKC# MT 58 forodesine hydrochloride 58 midstage clinical 58 RGB # 58 peripherally acting 58 Phase Ib clinical trials 58 CYT# vascular disrupting 58 multicenter Phase II 58 Hematide ™ 58 BiTE antibody 58 Aganocide 58 pharmacogenomic translational research 58 SNALP technology 58 Fx #A 58 delivers fluocinolone acetonide FA 58 CCR5 mAb 58 MVA BN R 58 Aflibercept 58 Cannabinor 58 histone deacetylase HDAC inhibitor 58 ENMD # 58 docetaxel Taxotere ® 58 Romidepsin 57 TransVax tm 57 virus HCV infection 57 cetuximab Erbitux R 57 NS5b 57 XL# XL# XL# XL# 57 nucleotide analog 57 Iluvien ® 57 multicenter Phase III 57 Panzem 57 Sapacitabine 57 PSN# [002] 57 PORxin TM 57 sapacitabine CYC# 57 Cloretazine ® 57 oral dihydropyrimidine dehydrogenase DPD 57 administered subcutaneously 57 LymphoStat B TM 57 castrate resistant prostate cancer 57 intranasal formulation 57 ALN TTR 57 HGS ETR2 57 Aurora kinase inhibitor 57 Elotuzumab 57 HCV polymerase 57 XOMA 3AB 57 JVRS 57 Zemiva TM 57 PRTX 57 candidate REP# 57 romazarit 57 TOCOSOL Paclitaxel 57 Ceflatonin R 57 ApoB SNALP 57 PEGylated Fab fragment 57 trastuzumab DM1 T DM1 57 4SC AG ISIN DE# 57 CRMD# 57 candidate AQ4N 57 GRNVAC1 57 protein kinase inhibitor 57 optimal dosing regimens 57 CTAP# Capsules 57 beta 1a 57 mGluR5 NAM 57 Aurexis 57 GVAX ® 57 phase IIa 57 tiapamil 57 Aurora kinase 57 cutaneous T 57 histone deacetylase inhibitor 57 CB2 selective receptor agonist 57 Azedra TM 57 sarcoma melanoma 57 Traficet EN 57 dacetuzumab SGN 57 alpha folate receptor 57 GW# [003] 57 Kinase Inhibitor 57 MCSP respectively 57 Epothilone D 57 volociximab 57 Phase Ib clinical 57 MTP inhibitor 57 Pimavanserin 57 mitogen activated ERK kinase 57 ASG 5ME 56 Alfacell proprietary ribonuclease 56 IMiDs R 56 TNFerade ™ 56 XP# XP# 56 Nanobody R 56 Phase IIa trials 56 XL# anticancer compounds 56 gefitinib Iressa 56 apricitabine ATC 56 adecatumumab MT# 56 hormone LHRH antagonist 56 VEGFR2 inhibitor 56 nicotinic alpha 7 56 SPC# [001] 56 Guanilib 56 HQK 56 trastuzumab Herceptin R 56 anti botulism antibody 56 Vascular Disrupting Agent 56 plasma kallikrein inhibitor 56 highly selective inhibitor 56 orally inhaled migraine 56 epothilones 56 taxane resistant 56 Phase Ib II 56 triciribine phosphate monohydrate 56 IMiDs ® 56 PORxin TM platforms 56 Hsp# Inhibitor 56 M2 subunit 56 lead Aganocide compound 56 IMiDs ® compound 56 Azedra 56 Phase #/#a 56 investigational protease inhibitor 56 non nucleoside inhibitor 56 HGS ETR1 mapatumumab 56 Plicera 56 Insegia 56 anticancer compound 56 anti CD3 monoclonal 56 Initiates Phase II 56 kidney urologic 56 candidate XP# 56 GATTEX ™ 56 protein tyrosine phosphatase 1B 56 personalized dendritic cell 56 ALN HPN 56 compound INCB# 56 Phase 2b Clinical Trial 56 Kosan dependence 56 generation URAT1 inhibitor 56 HCV NS5B polymerase 56 IL# PE#QQR 56 HGS# 56 Anthim 56 evaluating tivozanib 56 cell lymphoma CTCL 56 Altastaph 56 Hematide TM 56 preclinical efficacy 56 CD# CEA 56 Investigational Oral 56 Trofex TM 56 novel peptides 56 Begins Dosing 56 novel immunomodulatory 56 Presents Preclinical Data 56 delta opioid receptor 56 TRIOLEX ™ 56 allosteric modulator NAM 56 PSMA ADC 56 small molecule defensin 56 lymphoid malignancies 56 JAK2 Inhibitor 56 EVIZON TM squalamine lactate 56 TKM Ebola 56 refractory chronic lymphocytic 56 Bicifadine 56 OXi# 55 PHX# 55 radezolid 55 dyskinesia PD LID 55 enzastaurin 55 agonistic human 55 oral proteasome inhibitor 55 RNAi Therapeutic 55 Initiates Clinical Trial 55 ELACYT 55 PEG SN# 55 Quinamed 55 apoptosis proteins 55 Phase 1b clinical trials 55 apoptosis inducer 55 Poly ICLC 55 RenaZorb TM 55 Reports Preclinical Data 55 ALTROPANE R 55 Oracea TM 55 MEK inhibitor RDEA# 55 2 methoxyestradiol 55 investigational hepatitis C 55 Onalta 55 ADI PEG 55 IMPDH inhibitor 55 pan histone deacetylase 55 MET inhibitor 55 Zenvia ™ 55 GLPG# 55 pharmacokinetic PK study 55 recombinant subunit vaccine 55 Tarmogen 55 BCR ABL inhibitor 55 clinical trials SGN 55 Phase Ib study 55 CCX# 55 busulfan 55 candidate ATHX 55 development peramivir neuraminidase 55 telomerase inhibitor drug 55 recurrent glioblastoma multiforme 55 GLP toxicology studies 55 system REG1 consists 55 retaspimycin 55 oral Azacitidine 55 AQ4N 55 Bioral Amphotericin B 55 phase IIb study 55 LY# [003] 55 thiazolides 55 INCB# [001] 55 Tesetaxel 55 Ostabolin C TM 55 Locteron ® 55 topically applied SEPA 55 ImmunoVEX HSV2 55 ZFP Therapeutics 55 toenail onychomycosis 55 Zalypsis 55 initiated Phase Ib 55 vinca alkaloid 55 delivered RNAi therapeutic 55 compound ITMN 55 Initiates Clinical 55 BiTE R 55 PNT# 55 RNAi therapeutic targeting 55 MKC# MKC# PP 55 irreversible inhibitor 55 investigational compounds 55 huN# DM1 55 oncolytic virus therapies 55 stable nucleic acid 55 APOPTONE 55 tubulin inhibitor 55 Aurora Kinase 55 HCV polymerase inhibitors 55 selective androgen receptor modulator 55 EGEN 55 dextromethorphan quinidine 55 targets Galectin receptors 55 defensin mimetic antibiotic 55 Diamyd ® 55 entinostat 55 HCV nucleotide polymerase inhibitor 55 recombinant biopharmaceutical 55 AKT inhibitor 55 Phase IIa clinical trials 55 essential thrombocythemia ET 55 fosbretabulin 55 Ozarelix 55 preclinical studies 54 Phase 1b trial 54 Phase #/#a trial 54 orally dosed 54 OMNARIS HFA 54 cathepsin K inhibitor 54 HuCNS SC ® 54 Phase III Pivotal 54 human IgG1 monoclonal 54 Completes Patient Enrollment 54 HCD# [002] 54 neuronal nicotinic receptor NNR 54 Bezielle 54 INS# [001] 54 novel therapeutic antibodies 54 refractory CLL 54 PEGylated 54 anticoagulant reversing agent 54 Veronate R 54 PXD# 54 SPL# Gel vaginal microbicide 54 GLYX 54 Elusys 54 DNA methyltransferase inhibitors 54 PI3K/Akt pathway inhibitor 54 oral NKTR 54 Triolex 54 Fc fusion protein 54 investigational oral hepatitis C 54 SIX RO ROG 54 Homspera TM 54 oral ghrelin agonist 54 dihydrochloride Tablets 54 Initiate Phase 54 Protexia ® 54 VQD 54 initiate Phase 1b 54 Proellex TM 54 Entereg R 54 hyaluronidase enzyme 54 Presents Preclinical 54 TRANSDUR ® 54 gastro intestinal inflammation 54 NEUMUNE 54 μg dose 54 Chemophase 54 Vitaxin 54 seliciclib CYC# 54 AEGR 54 albiglutide 54 telomerase therapeutic 54 Selective Electrochemical Tumor Ablation 54 topical gel formulation 54 Triapine 54 AVN# [001] 54 TELINTRA R 54 PDX pralatrexate 54 demonstrated antitumor activity 54 Talotrexin 54 generation antisense 54 immunotoxin 54 potently inhibited 54 PKC# 54 H#N# VLP vaccine 54 world safest multivalent 54 Copegus ribavirin 54 TOCOSOL Camptothecin 54 Alocrest 54 sulfonylhydrazine class 54 HEPLISAV ™ 54 HSP# inhibitor 54 prokinetic agent 54 Presents Positive 54 accumulate preferentially 54 lesinurad 54 Aganocide ® 54 P#X# antagonist 54 Provectus Pharmaceuticals specializes 54 novel topoisomerase 54 PEGPH# 54 mapatumumab 54 epothilone 54 HIV integrase inhibitors 54 AzaSite Plus 54 hyperphenylalaninemia HPA due 54 secretory phospholipase A2 54 transcriptase inhibitor NNRTI 54 diabetes irritable bowel 54 LentiVector technology 54 Xcytrin R 54 REGN# 54 developing Zerenex ferric 54 TKB# 54 selectively inhibits 54 selective androgen receptor modulators 54 HuMax EGFr 54 ospemifene 53 Initiates Enrollment 53 Oral NKTR 53 velafermin belinostat 53 CD4 monoclonal antibody 53 candidate CRLX# 53 Pruvel TM 53 next generation URAT1 53 teplizumab 53 potent inhibitor 53 HDL Mimetic Peptide 53 GVAX R 53 AVE# 53 oral nucleoside analogue 53 UVIDEM 53 subcutaneous PRO 53 Rigel R# 53 erlotinib Tarceva ® 53 TRACON Pharmaceuticals 53 preclinical pharmacokinetic 53 PF # [001] 53 Curaxin 53 Triapine R 53 Trofex ™ 53 Tarvacin Anti Cancer 53 PTH analogue 53 drug conjugate 53 preclinical compounds 53 tumors GIST 53 RNA antagonists 53 solithromycin 53 NGX# 53 phase Ib 53 INSPIRE Trial Phase III 53 Phase 1a clinical 53 docetaxel Taxotere R 53 VentiRx Pharmaceuticals 53 thrombin component 53 favorable pharmacokinetic profile 53 imatinib Gleevec ® 53 forodesine HCl 53 sodium Injection 53 Zemiva ™ 53 Phase Ib 53 corticosteroid dexamethasone 53 commercialize CorMedix drug 53 DiLA2 53 Tezampanel 53 oral picoplatin 53 neratinib 53 Hsp# inhibitor 53 mda 7 53 PD LID 53 ocular formulation 53 Tumour Vascular Disrupting Agent 53 nilotinib Tasigna ® 53 RiVax 53 candidates bavituximab 53 pan BCR ABL 53 class anticancer quinolone 53 Acute Myeloid Leukemia AML 53 NASDAQ SNTA 53 Vicriviroc 53 imetelstat GRN#L 53 TRIOLEX HE# APOPTONE HE# 53 anionic backbone 53 ongoing Phase 1b 53 Locked Nucleic Acid 53 ABL inhibitor 53 HCV NS3 protease 53 axitinib 53 davunetide intranasal AL 53 multicenter Phase 53 Curaxin CBLC# 53 TKM PLK1 53 ALN VSP 53 Telik logo TELINTRA 53 telaprevir VX 53 Sulonex TM 53 lucinactant 53 Pharma Merck Serono 53 Genasense ® oblimersen 53 MT#/MEDI-# 53 YONDELIS 53 IPL# 53 EZN 53 adrenergic regulation 53 anti PlGF 53 novel orally administered 53 c Raf kinase 53 JAK2 kinase 53 Valortim 53 Alzhemed TM 53 INxin TM 53 anti amnesic 53 Cyclooxygenase Inhibiting Nitric Oxide 53 Polymerase Inhibitor 52 Inhalation Solution 52 NU# direct 52 Pharmos pipeline 52 ThermoDox ® clinical 52 Epothilones 52 compound PMX # 52 Jean Pierre Sommadossi Ph.D. 52 Junovan TM 52 AN# novel 52 romidepsin novel 52 mg RDEA# 52 phase III isavuconazole 52 secretory phospholipase A2 sPLA2 52 KNS # 52 TRAIL receptor antibodies 52 RAS MAPK pathway 52 clinical trials dacetuzumab SGN 52 AVONEX ® 52 virus AAV 52 FOLFOX6 chemotherapy regimen 52 PEG PAL 52 Neo Kidney Augment ™ 52 administered intranasally 52 generation Hsp# inhibitor 52 Parkinson disease levodopa induced 52 clinical trials lintuzumab SGN 52 Intermezzo ® zolpidem tartrate 52 Solazed ™ 52 pharmacological chaperone 52 selective kinase inhibitor 52 biodefense pathogens 52 GSK # 52 sunitinib Sutent ® 52 synthetic retinoid 52 KSP inhibitor 52 ALN TTR# 52 MKC# 52 novel histone deacetylase 52 Quinamed R 52 recombinant PSMA vaccine 52 gemcitabine cisplatin 52 MEK Inhibitor 52 activate SIRT1 52 PsychoGenics 52 Antibody Drug Conjugate 52 TRIOLEX 52 transthyretin mediated amyloidosis ATTR 52 inflammatory autoimmune diseases 52 Inc. www.micromet inc.com 52 NTDDS 52 TLR7 agonist 52 NASDAQ CGEN announced 52 monoclonal antibody conjugated 52 Protexia R 52 Phase 2b Trial 52 zolpidem tartrate sublingual tablet 52 CTA# Injection 52 vaccine GRNVAC1 52 inhibit oxidative stress 52 receptor inhibiting monoclonal 52 ANAVEX #-# [003] 52 hepatitis C polymerase inhibitor 52 Androxal TM 52 Nasdaq IDRA today 52 vapreotide acetate 52 lead molecular radiotherapeutic 52 IND enabling 52 Pentad TM 52 Phase 2a trial 52 GATTEX ® 52 5 HT6 antagonist 52 GLOBE NEWSWIRE Cyclacel Pharmaceuticals 52 metastatic castration resistant 52 preclinical 52 Dr. Fahar Merchant 52 initiated Phase 1b 52 CK # novel 52 pharmacogenetic test 52 Capesaris 52 developing Zerenex TM 52 reversible inhibitor 52 CORT # 52 Amigal TM 52 Neo Kidney Augment 52 bevacizumab Avastin R 52 peptidic compound 51 Survivin antagonist 51 metastatic renal cell 51 CYP#A# CYP#D# 51 measurable tumor regressions 51 Dr. Aiping Young 51 Ophena TM 51 SUVN 51 RDEA# 51 molecular chaperone regulation 51 anaplastic lymphoma kinase ALK 51 gastrointestinal disorders ATI 51 MORAb 51 gamma secretase inhibitor 51 product candidate Lpathomab 51 CXB# 51 Preclinical studies 51 Homspera ® 51 XL# inhibits 51 maximally tolerated dose 51 molecular imaging radiopharmaceuticals 51 bafetinib 51 HCV nucleoside polymerase inhibitors 51 personalized cellular immunotherapy 51 Actilon 51 dimebon latrepirdine 51 Nicotine Conjugate Vaccine 51 lipid nanoparticle 51 Affibody 51 INGN 51 PEGylated interferon 51 Exherin 51 pralatrexate injection folate analogue 51 Phase 2a clinical 51 skeletal sarcomere activators 51 please visit http:/www.vandapharma.com 51 Ostarine ™ 51 KL4 Surfactant 51 HCV RNA polymerase 51 inhibitor VX 51 Nasdaq PARD 51 novel L DOS# 51 solid tumors ZYBRESTAT 51 tivozanib AV 51 mg q#h 51 SparVax ™ 51 Vaxfectin R adjuvant 51 Georges Gemayel 51 CLORETAZINE TM VNP#M 51 non nucleoside polymerase 51 Valortim R 51 Arno Therapeutics 51 poly ADP ribose polymerase 51 nalbuphine ER 51 Metastatic Melanoma 51 Receives Fast Track 51 radiolabeled monoclonal antibody 51 ALN HTT 51 pDNA vaccine 51 hypoxia selective 51 product TNFerade TM 51 Inc. Nasdaq IMGN 51 Posiphen 51 arsenic trioxide injection 50 dosing cohort 50 ARRY # 50 BIM #A# 50 topical antifungal product 50 Therapeutic Competitors Companies 50 Crofelemer budesonide foam 50 lorvotuzumab mertansine 50 gastrin analogue TT 50 ANAVEX #-# [002] 50 NOX E# 50 IMiDs 50 intravesical infusion therapy 50 maturation inhibitor 50 PS# [001] 50 relapsed refractory multiple myeloma 50 SIRT1 activators 50 Kahalalide F 50 Lenocta 50 ORMD 50 CDK cyclin dependent 50 Empatic ™ 50 ostarine 50 drug pipeline TAFA# 50 CRx 50 lexidronam injection 50 HepeX B TM 50 acid phosphatase PAP 50 isatoribine 50 Nasdaq ENMD 50 GRN#L 50 nitric oxide donating 50 drug conjugate ADC 50 Aganocide R 50 ZFP Therapeutic 50 Asentar TM 50 modified glutathione analog 50 investigational drug 50 Tekmira SNALP stable 50 HER2 positive metastatic breast 50 generation HCV protease 50 hepatoprotective agent 50 Phase 1b 50 orally administered synthetic retinoid 50 Cariprazine 50 Debio 50 HIV RDEA# 50 Solorel TM 50 By JAMAAL ABDUL 50 cortisol synthesis 50 BCX# 50 5 FU leucovorin 50 integrin inhibitor 50 visit biotech.com 50 AQD class 50 Clay B. Siegall 50 ALTU 50 PCK# 50 urocortin 2 50 sulodexide 50 interferon gamma 1b 50 Azedra ™ 50 signal detection CTSD 50 adhesion molecule EpCAM expressing 50 ZFNs clinical trials 50 gallium containing 50 NASDAQ ARRY 50 TM Aganocide 49 please visit http:/www.sunesis.com 49 QLT# 49 oral ferric iron 49 ZEVALIN ® 49 Phase 2a 49 Pruvel ™ 49 HIV integrase inhibitor 49 oral Hsp# inhibitor 49 VISICOL R 49 budesonide MMX ® 49 EnVivo Pharmaceuticals 49 Sulonex 49 hematological tumors 49 evaluating satraplatin 49 developing ACAPODENE 49 bevirimat 49 Fc engineered 49 Hedgehog pathway inhibitor 49 Ovitrelle R Serostim 49 Luveris R Ovidrel R 49 preclinical toxicology 49 proprietary PEGylation 49 Inc. Nasdaq OXGN 49 FOLFOX chemotherapy 49 Anat Cohen Dayag 49 molecular therapeutics immunotherapies 49 generation FBPase inhibitor 49 Imetelstat 49 VLP vaccine 49 metabolism viral replication 49 IMPACS R 49 Aplidin R 49 Valortim ® 49 REVIVE Diabetes 49 evaluating T DM1 49 Through Glycoscience R 49 Phase Ia 49 markets COLAZAL 49 palifosfamide Zymafos TM 49 omecamtiv mecarbil formerly 49 Phase III ADT 49 COU AA 49 evaluating picoplatin 49 novel orally bioavailable 49 stage antibody MT# 49 deCODE chemistry 49 include PLX IBD 49 class oral heparinoid 49 Pharmos proprietary 49 novel synthetic peptide 49 DepoVax ™ 49 Canvaxin TM 49 CUDC 49 transthyretin TTR mediated amyloidosis 49 retaspimycin hydrochloride 49 clinical trials Archexin ® 49 commercializing oxidized glutathione 48 plus Copegus R 48 LE SN# 48 R MSCRAMM 48 Nasdaq PGNX today 48 catalytic antioxidant compounds 48 PEGylated irinotecan 48 clinical trials Archexin 48 NKTR 48 using ImmunoGen TAP 48 Telaprevir VX 48 cardiotoxic effects 48 markets Testim ® 48 IIa clinical 48 programs visit http:/www.bionovo.com 48 generation antisense compounds 48 IMiD 48 selective inverse agonist 48 Nasdaq DVAX 48 nucleotide polymerase inhibitor 48 Submits NDA 48 #mg/m# [001] 48 ATRA IV 48 Aztreonam lysine 48 humanised antibody 48 intermittent dosing 48 Genasense oblimersen sodium Injection 48 MVA HPV IL2 48 NASDAQ INGN 48 selectin antagonist 48 Budesonide foam crofelemer 48 ovulation suppression 48 Miraxion Amarin lead 48 GetGoal Phase III 48 OTCBB NRGX 48 Naglazyme R 48 ELND# AZD 48 Phase 2b clinical 48 ongoing Phase IIIb 48 ARRY 48 IIa trial 48 rFSH 48 cancer indications bafetinib 48 systemic lupus erythematosus lupus 48 NCCTG 48 candidate bevirimat PA 48 vivo preclinical 48 CoFactor 48 CORT # estimates 47 TEMSO 47 irinotecan doxorubicin oxaliplatin paclitaxel 47 PET FROM 47 Biopharmaceuticals AG 47 Trodusquemine 47 active AKT inhibitor 47 developing adecatumumab 47 please visit www.middlebrookpharma.com 47 DNA RNA Medicines 47 Zenvia TM 47 SB# ONX 47 Genasense R oblimersen 47 developing ostarine selective 47 please visit www.advaxis.com 47 treat refractory angina 47 PROSTASCINT R 47 Company AMEX SNT 47 symbol AVXL 47 improve impulse conduction 47 potent activator 47 Topline Results 47 SNS# T 47 Inc. NASDAQ GLGC 47 5 lipoxygenase activating 47 include Altastaph TM 47 pentadentate logo R 47 multiple ascending dose 47 selectively modulate 46 please visit www.metabolon.com 46 proprietary BiTE ® 46 pharmacological chaperones 46 resolvin 46 PRLX # 46 website http:/www.celsion.com 46 MSCRAMM ® 46 #F AV 46 please visit http:/www.atherogenics.com 46 memantine HCl 46 NASDAQ REGN 46 desvenlafaxine succinate 46 AKIP ™ 46 Merck Serono Nycomed 46 generation radiolabeled antibody 46 tumor regressions 46 malignant mesothelioma Alfacell 46 candidate FAV 46 vivo toxicology 45 Inc. NASDAQ TRGT 45 visit www.sciclone.com 45 visit www.targanta.com 45 YOUR LOCAL ANIMAL SHELTER 45 Genentech sanofi aventis 45 perifosine KRX 45 BiTE antibodies targeting 45 Predictive medicine 45 please visit www.tranzyme.com 45 transthyretin TTR 45 3 registrational trial 45 5 fluorouracil leucovorin 45 technology visit http:/www.genmab.com 45 CORLUX CORT # 45 Aeolus Pharmaceuticals Announces 45 Nabriva 45 website www.celsion.com 45 AAG KOS 45 Cephalon GlaxoSmithKline 45 novel antimitotic agent 45 carboplatin AUC 6 44 transdermal contraceptive 44 androgen receptor modulator 44 visit www.genmab.com 44 Sodium Sulfate Sodium Chloride 44 serious systemic Staphylococcal 44 Antigen Express website 44 include VALSTAR TM 44 RNAi therapeutic platform 44 progression TTP 44 Nasdaq OSIP 44 Merck OSI Pharmaceuticals 44 HIV maturation inhibition 44 affiliate Evogene Ltd. TASE 44 mg TID 44 compound CMX# 44 chemo radiotherapy 44 www.polymedix.com 44 SPP# [002] 44 sporozoite 44 Nventa proprietary CoVal 44 CORTOSS R 43 single ascending dose 43 catalytic antioxidants 43 Pediatric Oncology Branch 43 please visit www.sucampo.com 43 www.cellgenesys.com 43 R vancomycin hydrochloride 43 nucleoside tide 43 DNA demethylation 43 Nasdaq SGMO announced 43 Cytogen marketed